Adventrix: Thiovir Fights Bird Flu in Lab
Posted on: Monday, 20 March 2006, 15:00 CST
Adventrx said Monday its anti-viral Thiovir appears effective against chimeric strains of avian flu virus H5N1.
The company said that in preclinical studies, Thiovir worked against a chimeric avian/human influenza virus as well as influenza type A.
Adventrx said it tested its drug against a research-adapted H5N1 strain based on influenza A/Vietnam/1203/04 -- one of the deadly bird flu virus strains that is lethal in both humans and poultry -- and Ann Arbor/6/60. The firm said it would do more studies of Thiovir to assess its effectiveness against multiple H5N1 strains in both lab and in vivo trials.
We are encouraged by the results from two independent labs confirming Thiovir activity against multiple influenza viruses, said Adventrx President and Chief Executive Officer Evan Levine. We will continue to investigate Thiovir as a therapy for influenza viruses, including bird flu, and we look forward to announcing additional results, he said.
The company said it would present results from its preclinical studies of Thiovir at the 14th International Symposium on HIV and Emerging Infectious Diseases program in June in Toulon, France.
Source: United Press International
Related Articles
- U.S. Department of Health and Human Services and the Ad Council Launch New Nationwide PSA Campaign Urging Vaccination against the H1N1 Flu Virus
- SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus in Initial Pilot Animal Study
- How to Protect Against the Swine Flu Virus: 'My Personal Experience with Gene-Eden(TM), a Broad Range Antiviral Supplement'
- Study to Investigate AHCC and the Swine Flu Virus
- NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
- LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
- AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza; NEUGENE Antisense Efficacy Against Influenza Strains Reported at the International Conference on Antiviral Research
- AVI BioPharma Reports Confirmation of Efficacy Against Influenza Strains
- WHO Asks Vietnam to Assist in Creating Vaccine Against Human Bird Flu Virus
- Vietnam to Begin Testing VIRA 38 Against the Bird Flu Virus (H5N1)
 |
 |
User Comments (0)
RSS Feeds